SCHEMBL29504064

SCHEMBL29504064

CC(C)=CCC/C(C)=C/CC/C(C)=C/CCO[Si](C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.59
ALOX15 P16050 3/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 2/20 0.53
CYP3A4 P08684 2/20 0.53
ALDH1A1 P00352 2/20 0.53
UGT1A1 P22309 1/20 0.53
SQLE Q14534 7/20 0.52
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751818 0.82 ALOX15 (0.56) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL3751814 0.82 ALOX15 (0.56) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL12997108 0.82 ALOX15 (0.56) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL28342394 0.79 KMT2A (0.70) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL27437786 0.79 KMT2A (0.70) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL19841923 0.78 KMT2A (0.67) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL23802597 0.76 KMT2A (1.00) KMT2AALOX15MAPTMEN1CYP3A4
Squalene SCHEMBL8819997 0.76 KMT2A (1.00) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL8013144 0.76 KMT2A (1.00) KMT2AALOX15MAPTMEN1CYP3A4
SCHEMBL21639794 0.76 KMT2A (1.00) KMT2AALOX15MAPTMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062725-A1 METHOD FOR PURIFYING (-)-AMBROX GIVAUDAN SA (CH) 2026-03-05 US disclosed
US-20260043058-A1 SHC ENZYMES AND ENZYME VARIANTS GIVAUDAN SA (CH) 2026-02-12 US disclosed
US-20250361536-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS GIVAUDAN SA (CH) 2025-11-27 US disclosed
US-12416027-B2 Squalene hopene cyclase (SHC) variants GIVAUDAN SA (CH) 2025-09-16 US disclosed
EP-4613868-A2 SQUALENE HOPENE CYCLASE DERIVATIVES AND USE THEREOF FOR PRODUCING AMBROX International Flavors & Fragrances Inc. (US) 2025-09-10 EP disclosed
US-12404531-B2 Method for purifying (−)-Ambrox GIVAUDAN SA (CH) 2025-09-02 US disclosed
EP-4208546-B1 SQUALENE HOPENE CYCLASE DERIVATIVES AND USE THEREOF FOR PRODUCING AMBROX INT FLAVORS & FRAGRANCES INC (US) 2025-05-21 EP disclosed
EP-4493685-A1 SHC ENZYMES AND ENZYME VARIANTS Givaudan SA (CH) 2025-01-22 EP disclosed
CN-119137269-A SHC enzyme and enzyme variants 奇华顿股份有限公司 2024-12-13 CN disclosed
US-20240368647-A1 ENZYMES AND APPLICATIONS THEREOF PROTEUS SA (FR) 2024-11-07 US disclosed
US-20230220431-A1 ENZYMES AND APPLICATIONS THEREOF GIVAUDAN SA (CH) 2023-07-13 US disclosed
EP-4208546-A2 SQUALENE HOPENE CYCLASE DERIVATIVES AND USE THEREOF FOR PRODUCING AMBROX International Flavors & Fragrances Inc. (US) 2023-07-12 EP disclosed
US-20230212624-A1 METHOD FOR PURIFYING (-)-AMBROX GIVAUDAN SA (CH) 2023-07-06 US disclosed
CN-116348602-A Squalene-hopene cyclase derivatives and their use for the production of ambrox 国际香料和香精公司 2023-06-27 CN disclosed
US-20230021613-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS GIVAUDAN SA (CH) 2023-01-26 US disclosed
EP-4069836-A1 SQUALENE HOPENE CYCLASE (SHC) VARIANTS Givaudan SA (CH) 2022-10-12 EP disclosed
US-11466299-B2 Enzymes and applications thereof GIVAUDAN S.A. (CH) 2022-10-11 US disclosed
CN-115052982-A Squalene agamene cyclase (SHC) variants 奇华顿股份有限公司 2022-09-13 CN disclosed
CN-114438147-A Enzyme and use thereof 奇华顿股份有限公司 2022-05-06 CN disclosed
WO-2022051761-A2 SQUALENE HOPENE CYCLASE DERIVATIVES AND USE THEREOF FOR PRODUCING AMBROX INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368647-A1 ENZYMES AND APPLICATIONS THEREOF HAO1, HLCS, HACL2 KMT2A 3229/4885ALOX15 1237/4885MAPT 4855/4885
US-20260043058-A1 SHC ENZYMES AND ENZYME VARIANTS SQLE, DHCR7, CYP51A1 KMT2A 3526/4885ALOX15 231/4885MAPT 4866/4885
US-20230220431-A1 ENZYMES AND APPLICATIONS THEREOF HAO1, HLCS, HACL2 KMT2A 3229/4885ALOX15 1237/4885MAPT 4855/4885
US-20260062725-A1 METHOD FOR PURIFYING (-)-AMBROX TAS2R7, TAS2R3, TAS2R13 KMT2A 3026/4885ALOX15 1324/4885MAPT 3797/4885
US-11466299-B2 Enzymes and applications thereof HAO1, HLCS, HACL2 KMT2A 3229/4885ALOX15 1237/4885MAPT 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.